| Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a … MCA Palanca-Wessels, M Czuczman, G Salles, S Assouline, LH Sehn, ... The Lancet Oncology 16 (6), 704-715, 2015 | 335 | 2015 |
| Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status MS Gordon, D Matei, C Aghajanian, UA Matulonis, M Brewer, GF Fleming, ... Journal of Clinical Oncology 24 (26), 4324-4332, 2006 | 306 | 2006 |
| Bioanalytical assay strategies for the development of antibody–drug conjugate biotherapeutics S Kaur, K Xu, OM Saad, RC Dere, M Carrasco-Triguero Bioanalysis 5 (2), 201-226, 2013 | 230 | 2013 |
| DCDT2980S, an anti-CD22-monomethyl auristatin E antibody–drug conjugate, is a potential treatment for non-Hodgkin lymphoma D Li, KA Poon, SF Yu, R Dere, MA Go, J Lau, B Zheng, K Elkins, ... Molecular cancer therapeutics 12 (7), 1255-1265, 2013 | 111 | 2013 |
| Characterization of the drug-to-antibody ratio distribution for antibody–drug conjugates in plasma/serum K Xu, L Liu, R Dere, E Mai, R Erickson, A Hendricks, K Lin, JR Junutula, ... Bioanalysis 5 (9), 1057-1071, 2013 | 106 | 2013 |
| Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma AG Polson, M Williams, AM Gray, RN Fuji, KA Poon, J McBride, H Raab, ... Leukemia 24 (9), 1566-1573, 2010 | 100 | 2010 |
| Phase I study of the anti-CD22 antibody–drug conjugate pinatuzumab vedotin with/without rituximab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma RH Advani, D Lebovic, A Chen, M Brunvand, A Goy, JE Chang, ... Clinical Cancer Research 23 (5), 1167-1176, 2017 | 80 | 2017 |
| PK assays for antibody–drug conjugates: case study with ado-trastuzumab emtansine R Dere, JH Yi, C Lei, OM Saad, C Huang, Y Li, J Baudys, S Kaur Bioanalysis 5 (9), 1025-1040, 2013 | 75 | 2013 |
| Immunogenicity assays for antibody–drug conjugates: case study with ado-trastuzumab emtansine M Carrasco-Triguero, JH Yi, R Dere, ZJ Qiu, C Lei, Y Li, C Mahood, ... Bioanalysis 5 (9), 1007-1023, 2013 | 61 | 2013 |
| Phase Ia study of anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin DNIB0600A in patients with non–small cell lung cancer and platinum-resistant ovarian cancer DE Gerber, JR Infante, MS Gordon, SB Goldberg, M Martín, E Felip, ... Clinical Cancer Research 26 (2), 364-372, 2020 | 43 | 2020 |
| Interaction of wild-type and catalytically inactive mutant forms of tissue-type plasminogen activator with human umbilical vein endothelial cell monolayers. V Ramakrishnan, DV Sinicropi, R Dere, WC Darbonne, KB Bechtol, ... Journal of Biological Chemistry 265 (5), 2755-2762, 1990 | 43 | 1990 |
| Immunogenicity of antibody–drug conjugates: Observations across 8 molecules in 11 clinical trials M Carrasco-Triguero, RC Dere, M Milojic-Blair, OM Saad, D Nazzal, ... Bioanalysis 11 (17), 1555-1568, 2019 | 33 | 2019 |
| Integrated two‐analyte population pharmacokinetic model of polatuzumab vedotin in patients with non‐Hodgkin lymphoma D Lu, T Lu, L Gibiansky, X Li, C Li, P Agarwal, CS Shemesh, R Shi, ... CPT: Pharmacometrics & Systems Pharmacology 9 (1), 48-59, 2020 | 30 | 2020 |
| Evaluation and use of an anti‐cynomolgus monkey CD79b surrogate antibody–drug conjugate to enable clinical development of polatuzumab vedotin D Li, D Lee, RC Dere, B Zheng, SF Yu, FK Fuh, KR Kozak, S Chung, ... British Journal of Pharmacology 176 (19), 3805-3818, 2019 | 25 | 2019 |
| Anti‐CD22 and anti‐CD79b antibody‐drug conjugates preferentially target proliferating B cells FK Fuh, C Looney, D Li, KA Poon, RC Dere, DM Danilenko, J McBride, ... British Journal of Pharmacology 174 (8), 628-640, 2017 | 23 | 2017 |
| Semi-mechanistic multiple-analyte pharmacokinetic model for an antibody-drug-conjugate in cynomolgus monkeys D Lu, JY Jin, S Girish, P Agarwal, D Li, S Prabhu, RC Dere, OM Saad, ... Pharmaceutical Research 32, 1907-1919, 2015 | 20 | 2015 |
| Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia DD Leipold, I Figueroa, S Masih, B Latifi, V Yip, BQ Shen, RC Dere, ... MAbs 10 (8), 1312-1321, 2018 | 17 | 2018 |
| Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma CS Shemesh, P Agarwal, T Lu, C Lee, RC Dere, X Li, C Li, JY Jin, S Girish, ... Cancer chemotherapy and pharmacology 85, 831-842, 2020 | 14 | 2020 |
| Application of a two-analyte integrated population pharmacokinetic model to evaluate the impact of intrinsic and extrinsic factors on the pharmacokinetics of polatuzumab … D Lu, T Lu, R Shi, L Gibiansky, P Agarwal, CS Shemesh, RC Dere, ... Pharmaceutical Research 37, 1-16, 2020 | 9 | 2020 |
| Integrated Two‐Analyte Population Pharmacokinetic Model for Antibody–Drug Conjugates in Patients: Implications for Reducing Pharmacokinetic Sampling D Lu, L Gibiansky, P Agarwal, RC Dere, C Li, YW Chu, J Hirata, A Joshi, ... CPT: Pharmacometrics & Systems Pharmacology 5 (12), 665-673, 2016 | 9 | 2016 |
